Literature DB >> 22935971

The molecular basis for neuroimmune receptor signaling.

Thomas J Rogers.   

Abstract

Many of the receptors which are responsible for the responses to the common drugs of abuse belong to the G protein-coupled receptor (GPCR) family. In this special issue of the Journal of Neuroimmune Pharmacology a collection of papers is presented which deals with signaling events that are important for the function of these receptors. Because these receptors are expressed by both neuronal and immune cells, and because these receptors play a complex role in regulating function in both the nervous and immune systems, a more complete understanding of the regulation of expression of these receptors is essential. Moreover, once these receptors are expressed and activated, a complex series of signaling events are initiated that can have substantial significance. We have only a limited understanding of these signaling events, but with more complete information, we may be able to control the undesirable and/or desirable consequences of receptor activation by drugs of abuse.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22935971      PMCID: PMC4011130          DOI: 10.1007/s11481-012-9398-4

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN: 1557-1890            Impact factor:   4.147


  7 in total

Review 1.  CXCL12 signaling in the development of the nervous system.

Authors:  Divakar S Mithal; Ghazal Banisadr; Richard J Miller
Journal:  J Neuroimmune Pharmacol       Date:  2012-01-21       Impact factor: 4.147

Review 2.  MicroRNAs in opioid pharmacology.

Authors:  Cheol Kyu Hwang; Yadav Wagley; Ping-Yee Law; Li-Na Wei; Horace H Loh
Journal:  J Neuroimmune Pharmacol       Date:  2011-11-09       Impact factor: 4.147

3.  Trace amine associated receptor 1 signaling in activated lymphocytes.

Authors:  Michael W Panas; Zhihua Xie; Helen N Panas; Marius C Hoener; Eric J Vallender; Gregory M Miller
Journal:  J Neuroimmune Pharmacol       Date:  2011-10-29       Impact factor: 4.147

4.  Morphine and gp120 toxic interactions in striatal neurons are dependent on HIV-1 strain.

Authors:  Elizabeth M Podhaizer; Shiping Zou; Sylvia Fitting; Kimberly L Samano; Nazira El-Hage; Pamela E Knapp; Kurt F Hauser
Journal:  J Neuroimmune Pharmacol       Date:  2011-11-19       Impact factor: 4.147

5.  The endocannabinoids anandamide and virodhamine modulate the activity of the candidate cannabinoid receptor GPR55.

Authors:  Haleli Sharir; Linda Console-Bram; Christina Mundy; Steven N Popoff; Ankur Kapur; Mary E Abood
Journal:  J Neuroimmune Pharmacol       Date:  2012-03-28       Impact factor: 4.147

6.  Δ9-tetrahydrocannabinol suppresses cytotoxic T lymphocyte function independent of CB1 and CB 2, disrupting early activation events.

Authors:  Peer W F Karmaus; Weimin Chen; Barbara L F Kaplan; Norbert E Kaminski
Journal:  J Neuroimmune Pharmacol       Date:  2011-07-26       Impact factor: 4.147

7.  Regulation of mu opioid receptor expression in developing T cells.

Authors:  Lily Zhang; Judith Sliker Belkowski; Tammi Briscoe; Thomas J Rogers
Journal:  J Neuroimmune Pharmacol       Date:  2012-08-25       Impact factor: 4.147

  7 in total
  5 in total

1.  Change in evolution.

Authors:  Howard E Gendelman
Journal:  J Neuroimmune Pharmacol       Date:  2012-11-13       Impact factor: 4.147

2.  Design and synthesis of a bivalent probe targeting the putative mu opioid receptor and chemokine receptor CXCR4 heterodimer.

Authors:  Bethany A Reinecke; Guifeng Kang; Yi Zheng; Samuel Obeng; Huijun Zhang; Dana E Selley; Jing An; Yan Zhang
Journal:  RSC Med Chem       Date:  2019-12-19

Review 3.  Psychedelics and Immunomodulation: Novel Approaches and Therapeutic Opportunities.

Authors:  Attila Szabo
Journal:  Front Immunol       Date:  2015-07-14       Impact factor: 7.561

4.  Dimethyltryptamine (DMT): a biochemical Swiss Army knife in neuroinflammation and neuroprotection?

Authors:  Attila Szabo; Ede Frecska
Journal:  Neural Regen Res       Date:  2016-03       Impact factor: 5.135

Review 5.  Mycotherapy: Potential of Fungal Bioactives for the Treatment of Mental Health Disorders and Morbidities of Chronic Pain.

Authors:  Elaine Meade; Sarah Hehir; Neil Rowan; Mary Garvey
Journal:  J Fungi (Basel)       Date:  2022-03-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.